 SAN DIEGO, July 21, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento announced today its partner Escugen Biotechnology Co, Ltd. Escugen and Sorrentos subsidiary Levena Suzhou Biopharma Co., Ltd. Levena have received an approval letter from the Center for Drug Evaluation CDE of the National Medical Products Administration NMPA for its Application for Clinical Trial Acceptance No. CXSL2101069 of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate. 